We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OREX
201
DELISTED
Orexigen Therapeutics, Inc.
OREX
$57K ﹤0.01%
+19,700
New +$59.1K
OREX
202
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$57K ﹤0.01%
197
– –
VTGN icon
203
VistaGen Therapeutics
VTGN
$9.7M
$48K ﹤0.01%
851
-4,932
-85% -$289K
GENE
204
DELISTED
Genetic Technologies Ltd.
GENE
$48K ﹤0.01%
2,681
-25,823
-91% -$541K
SRNE
205
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$35K ﹤0.01%
+17,300
New +$33.8K
CRIS icon
206
CALL
Curis
CRIS
$9.78M
– –
0
– –
BNTCW
207
DELISTED
Benitec Biopharma Limited
BNTCW
$32K ﹤0.01%
90,193
-34,970
-28% -$12.2K
CHRN
208
PUT
ChronoScale Holdings
CHRN
$2.94B
$30K ﹤0.01%
1
– –
GPL
209
DELISTED
Great Panther Mining Limited
GPL
$22K ﹤0.01%
+1,732
New +$22.3K
CAPR icon
210
Capricor Therapeutics
CAPR
$380M
$20K ﹤0.01%
2,420
-21,339
-90% -$390K
OASM
211
DELISTED
Oasmia Pharmaceutical AB
OASM
$20K ﹤0.01%
19,000
-16,054
-46% -$28.3K
LJPC
212
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
$19K ﹤0.01%
346
-707
-67% -$20.3K
CYTR
213
PUT
DELISTED
CytRx Corp
CYTR
$16K ﹤0.01%
+43
New +$147
NSPR icon
214
InspireMD
NSPR
$32.3M
$15K ﹤0.01%
1
-8
-89% -$128K
IMUC.WS
215
DELISTED
ImmunoCellular Therapeutics Ltd.
IMUC.WS
$8K ﹤0.01%
415,103
-3,664
-0.9% -$639
NUROW
216
DELISTED
NeuroMetrix, Inc. Warrants
NUROW
$7K ﹤0.01%
6,502
-30,338
-82% -$66.7K
ABBV icon
217
PUT
AbbVie
ABBV
$470B
– –
-714
Closed -$4.65M
ALKS icon
218
CALL
Alkermes
ALKS
$8.49B
– –
-708
Closed -$418K
AMGN icon
219
CALL
Amgen
AMGN
$213B
– –
-798
Closed -$13.1M
AMGN icon
220
Amgen
AMGN
$213B
– –
-37,104
Closed -$6.09M
AMGN icon
221
PUT
Amgen
AMGN
$213B
– –
-3,055
Closed -$50.1M
ARDX icon
222
PUT
Ardelyx
ARDX
$1.25B
– –
-160
Closed -$40K
BMRN icon
223
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-1,969
Closed -$17.3M
BPMC
224
DELISTED
Blueprint Medicines
BPMC
– –
-50,000
Closed -$2M
CANF
225
Can-Fite BioPharma American Depositary Shares
CANF
$6.75M
– –
-10
Closed -$57K
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.